Evidence map›Paper›PMID 37369463›Full record

Trial reportIn vivo (Athens, Greece)

Therapeutic Efficacy of AFree Oral Spray on the Symptoms and Course of Moderate and Severe COVID-19 in the Field Hospital.

Duong T Tran, Truong N Pham, Nhung H T Nguyen, Hau D Tran, Huy Q Hoang, Anh K Nguyen, B O Han, Ba X Hoang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duong T Tran19-8 Hospital, Ministry of Public Security, Hanoi, Vietnam.
Truong N Pham19-8 Hospital, Ministry of Public Security, Hanoi, Vietnam.
Nhung H T NguyenDepartment of Clinical Laboratory, University of Medical Technology, Hai Duong, Vietnam.
Hau D TranDepartment of Oncology, National Children Hospital, Hanoi, Vietnam.
Huy Q HoangNatural Health Medical Center, Lawndale, CA, U.S.A.
Anh K NguyenInventive Medical Foundation, South El Monte, CA, U.S.A.
B O HanNimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A.
Ba X HoangNimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A. baxuanho@usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimA prospective randomized, open-label, single-blinded clinical trial was conducted to evaluate the efficacy of AFree on the symptoms and course of moderate and severe COVID-19 in the field hospital. PATIENTS AND

methodsTwo hundred hospitalized patients diagnosed with COVID-19 were enrolled. The patients were randomized into 100 patients in the interventional AFree group and 100 in the control group. The AFree group patients were treated with AFree oral spray in conjunction with the standard COVID-19 treatment protocol, while the control group of patients were treated with only standard care.

resultsPatients of the AFree group demonstrated a remarkedly faster improvement in all COVID-19-related symptoms, resulting in a shorter time for complete recovery than the control group. More importantly, they showed a shorter time for complete viral clearance. Adding AFree to the standard of care protocol also significantly improved the restoration of taste and smell and reduced lung infiltration. Additionally, the patients in the AFree group also exhibited fewer adverse effects related to treatment.

conclusionAFree oral spray is a simple-to-use, safe, and effective adjunctive treatment for moderate and severe COVID-19 cases. AFree oral spray was demonstrated to potentially be effective for COVID-19 prevention.

Indexed as

COVID-19COVID-19 Drug TreatmentHumansMobile Health UnitsOral SpraysProspective StudiesSARS-CoV-2Treatment OutcomeOral SpraysAFreeCOVID-19dimethyl sulfoxideDMSOIodideSARS-CoV-2viral infectionZinc

Identifiers

PMID37369463
PMCPMC10347933

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.